Sidewinder Therapeutics secures $137 million in Series B financing, co-led by Frazier Life Sciences and Novartis Venture Fund, to advance bispecific ADCs for cancer treatment.
Amount Raised
$137 Million
Round Type
Series B
Investors
Description
Sidewinder Therapeutics, a biopharmaceutical company, announced an oversubscribed $137 million Series B financing to further its development of bispecific ADCs for cancer. The financing was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from several notable investors. This funding will help advance their innovative therapies into clinical development. The company aims to lead the way in next-generation treatments for difficult-to-treat cancers.
Quick answer
Sidewinder Therapeutics raised $137 Million in a Series B round, dated April 8, 2026. Investors: Orbimed, Samsara Biocapital, Life Sciences At Goldman Sachs Alternatives, DCVC Bio, Longwood Fund, Astellas Venture Management, Alexandria Venture Investments and Frazier Life Sciences.
- How much did Sidewinder Therapeutics raise?
- Sidewinder Therapeutics raised $137 Million in a Series B round on April 8, 2026.
- Who invested in Sidewinder Therapeutics?
- Orbimed, Samsara Biocapital, Life Sciences At Goldman Sachs Alternatives, DCVC Bio, Longwood Fund, Astellas Venture Management, Alexandria Venture Investments and Frazier Life Sciences are named as investors in this round.
- What does Sidewinder Therapeutics do?
- Sidewinder Therapeutics is a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Sidewinder Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- HCW Biologics raised $4M on May 21, 2026.
- Citius Oncology raised $37M on May 6, 2026.
- Windward Bio raised $165M (Funding Round) on May 5, 2026.
- Lighthouse Pharmaceuticals raised $15M (Series A) on April 22, 2026.
- Sparian Biosciences raised $15M (Grant) on April 13, 2026.
- Denali Therapeutics raised $200M (Debt Financing) on March 31, 2026.
Who to call at Sidewinder Therapeutics, and when
A new round usually means Sidewinder Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sidewinder Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sidewinder Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sidewinder Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sidewinder Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansSidewinder Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.